Skip to main content
SpringerLink
Log in

Pulmonary Erdheim-Chester disease successfully treated with vemurafenib

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Heritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O (2016) Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 6(2):154–165. https://doi.org/10.1158/2159-8290.CD-15-0913

    Article  CAS  PubMed  Google Scholar 

  2. Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martinez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM (2018) Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 4(3):384–388. https://doi.org/10.1001/jamaoncol.2017.5029

    Article  PubMed  Google Scholar 

  3. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373(8):726–736. https://doi.org/10.1056/NEJMoa1502309

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Toledano D, Barete S, Charlotte F, Cluzel P, Donadieu J, Benameur N, Grenier PA, Besnard S, Ory JP, Lifermann F, Idbaih A, Granel B, Graffin B, Hervier B, Arnaud L, Amoura Z (2015) Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol 33(5):411–418. https://doi.org/10.1200/JCO.2014.57.1950

    Article  CAS  PubMed  Google Scholar 

  5. Cohen Aubart F, Emile JF, Carrat F, Charlotte F, Benameur N, Donadieu J, Maksud P, Idbaih A, Barete S, Hoang-Xuan K, Amoura Z, Haroche J (2017) Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood 130(11):1377–1380. https://doi.org/10.1182/blood-2017-03-771873

    Article  CAS  PubMed  Google Scholar 

  6. Mirmomen SM, Sirajuddin A, Nikpanah M, Symons R, Paschall AK, Papageorgiou I, Gahl WA, O’Brien K, Estrada-Veras JI, Malayeri AA (2018) Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAF(V600E) mutation. Eur Radiol 28(11):4635–4642. https://doi.org/10.1007/s00330-018-5421-3

    Article  PubMed  Google Scholar 

  7. Wang JN, Wang FD, Sun J, Liang ZY, Li J, Zhou DB, Tian X, Cao XX (2021) Pulmonary manifestations of Erdheim-Chester disease: clinical characteristics, outcomes and comparison with Langerhans cell histiocytosis. Br J Haematol 194(6):1024–1033. https://doi.org/10.1111/bjh.17712

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was funded by Beijing Natural Science Haidian Frontier Foundation (Grant No. L222081 to CXX), the National High Level Hospital Clinical Research Funding (Grant No. 2022-PUMCH-B-046 to CXX), and the National High Level Hospital Clinical Research Funding (Grant No. 2022-PUMCH-A-260 to SKN).

Author information

Author notes

  1. Kai-ni Shen and Long Chang contributed equally to this study.

Authors and Affiliations

  1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China

    Kai-ni Shen, Long Chang, Jian Li & Xin-xin Cao

  2. State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Kai-ni Shen, Long Chang, Jian Li & Xin-xin Cao

  3. Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Na Niu

Authors
  1. Kai-ni Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Long Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Na Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xin-xin Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SKN and CXX contributed to the concept and design of the case report. SKN and CL performed chart review, collected clinical data, and drafted the manuscript. NN aided in image selection and interpretation of clinical data. CXX aided in interpretation of clinical data and utilization of specialty specific clinical expertise to critically review and revise the manuscript. All authors critically reviewed the manuscript and approved the final version.

Corresponding author

Correspondence to Xin-xin Cao.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Patient consent statement

Written informed consent was obtained from the patient included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shen, Kn., Chang, L., Niu, N. et al. Pulmonary Erdheim-Chester disease successfully treated with vemurafenib. Ann Hematol 103, 673–675 (2024). https://doi.org/10.1007/s00277-023-05534-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05534-6

Search

Navigation